[go: up one dir, main page]

CL2019001658A1 - Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos. - Google Patents

Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos.

Info

Publication number
CL2019001658A1
CL2019001658A1 CL2019001658A CL2019001658A CL2019001658A1 CL 2019001658 A1 CL2019001658 A1 CL 2019001658A1 CL 2019001658 A CL2019001658 A CL 2019001658A CL 2019001658 A CL2019001658 A CL 2019001658A CL 2019001658 A1 CL2019001658 A1 CL 2019001658A1
Authority
CL
Chile
Prior art keywords
pyrimidine derivatives
compounds
tricyclic enone
rory
inhibition
Prior art date
Application number
CL2019001658A
Other languages
English (en)
Inventor
Xin Jiang
Christopher F Bender
Melean Visnick
Martha R Hotema
Zachary S Sheldon
Chitase Lee
Bradley William Caprathe
Gary Bolton
Brian Kornberg
Original Assignee
Reata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc
Publication of CL2019001658A1 publication Critical patent/CL2019001658A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

EN LA PRESENTE, SE DESCRIBEN COMPUESTOS DE LAS FÓRMULAS, ASÍ COMO ANÁLOGOS DE ESTOS, DONDE LAS VARIABLES SE DEFINEN EN LA PRESENTE. TAMBIÉN SE PROPORCIONAN COMPOSICIONES FARMACÉUTICAS DE ESTOS. EN ALGUNOS ASPECTOS, LOS COMPUESTOS Y LAS COMPOSICIONES QUE SE PROPORCIONAN EN LA PRESENTE PUEDEN USARSE PARA INHIBIR RORΓ Y/O REDUCIR LA EXPRESIÓN DE LA IL-17. TAMBIÉN SE PROPORCIONAN MÉTODOS DE ADMINISTRACIÓN DE COMPUESTOS Y LA COMPOSICIÓN QUE SE PROPORCIONAN EN LA PRESENTE A UN PACIENTE QUE LO NECESITE, POR EJEMPLO, PARA EL TRATAMIENTO O LA PREVENCIÓN DE ENFERMEDADES O TRASTORNOS ASOCIADOS A TRASTORNOS AUTOINMUNITARIOS O INFLAMACIÓN.
CL2019001658A 2016-12-16 2019-06-14 Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos. CL2019001658A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662435588P 2016-12-16 2016-12-16

Publications (1)

Publication Number Publication Date
CL2019001658A1 true CL2019001658A1 (es) 2019-09-27

Family

ID=61028153

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001658A CL2019001658A1 (es) 2016-12-16 2019-06-14 Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos.

Country Status (20)

Country Link
US (3) US11292781B2 (es)
EP (1) EP3555062A1 (es)
JP (1) JP7177059B2 (es)
KR (2) KR20240019389A (es)
CN (1) CN110248932B (es)
AU (1) AU2017377852C1 (es)
BR (1) BR112019012271A2 (es)
CA (2) CA3046183C (es)
CL (1) CL2019001658A1 (es)
CO (1) CO2019007409A2 (es)
EA (1) EA201991387A1 (es)
IL (1) IL267274B2 (es)
MX (1) MX2019007088A (es)
NZ (1) NZ754764A (es)
PE (1) PE20191490A1 (es)
PH (1) PH12019501371A1 (es)
TW (1) TWI831738B (es)
UA (1) UA127376C2 (es)
WO (1) WO2018111315A1 (es)
ZA (1) ZA201904227B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA019263B1 (ru) 2008-04-18 2014-02-28 Ритэ Фамэсутикл, Инк. Антиоксидативные модуляторы воспаления: производные олеанолевой кислоты с аминовыми и другими модификациями на с-17
ES2634315T3 (es) 2012-04-27 2017-09-27 Reata Pharmaceuticals, Inc. Derivados de 2.2-difluoropropionamida de bardoxolona metilo, formas polimórficas y métodos de uso de los mismos
WO2016130927A1 (en) * 2015-02-12 2016-08-18 Reata Pharmaceuticals, Inc. Imidazolyl tricyclic enones as antioxidant iflammation modulators
SI3433256T1 (sl) 2016-10-24 2019-11-29 Astrazeneca Ab Derivat 6,7,8,9-tetrahidro-3H-pirazolo(4,3-f)izokinolina uporabni v zdravljenju raka
TWI831738B (zh) * 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
HUE047761T2 (hu) 2017-01-30 2020-05-28 Astrazeneca Ab Ösztrogén receptor modulátorok
CA3089134A1 (en) * 2018-01-29 2019-08-01 Capulus Therapeutics, Llc Srebp inhibitors comprising a 6-membered central ring
CN112654610B (zh) 2018-06-15 2024-12-24 里亚塔医药公司 用于抑制IL-17和RORγ的吡唑和咪唑化合物
WO2019246461A1 (en) 2018-06-20 2019-12-26 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
US20210330653A1 (en) 2020-04-24 2021-10-28 Astrazeneca Ab Dosage Regimen for the Treatment of Cancer
JP7719796B2 (ja) 2020-04-24 2025-08-06 アストラゼネカ・アクチエボラーグ 医薬製剤
CA3188292A1 (en) * 2020-08-07 2022-02-10 Kazuhiko Shigeno Novel cycloalkenone compound or salt thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
EP1142889A1 (en) 2000-04-03 2001-10-10 Pfizer Products Inc. Pyrazole derivatives as anti-inflammatory/analgesic agents
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
CA2430454A1 (en) 2000-11-28 2002-06-20 Board Of Regents, The University Of Texas System Cddo-compounds and combination therapies thereof
WO2003027075A2 (en) 2001-09-19 2003-04-03 Pharmacia Corporation Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
US7176237B2 (en) 2002-01-15 2007-02-13 The Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
US6974801B2 (en) 2002-05-13 2005-12-13 The Trustees Of Dartmounth College Inhibitors and methods of use thereof
WO2006089406A1 (en) 2005-02-22 2006-08-31 Gemin X Biotechnologies Inc. Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents
US8299046B2 (en) 2006-11-17 2012-10-30 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
CA2670099A1 (en) 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
WO2009023845A2 (en) 2007-08-15 2009-02-19 The Board Of Regents Of The University Of Texas System Combination therapy with synthetic triterpenoids and gemcitabine
EP2252283B9 (en) 2008-01-11 2019-03-20 Reata Pharmaceuticals, Inc. Synthetic triterpenoids and methods of use in the treatment of disease
NZ588708A (en) 2008-04-18 2012-09-28 Reata Pharmaceuticals Inc 2-cyano steroid derivatives including an anti-inflammatory pharmacore
EA019263B1 (ru) 2008-04-18 2014-02-28 Ритэ Фамэсутикл, Инк. Антиоксидативные модуляторы воспаления: производные олеанолевой кислоты с аминовыми и другими модификациями на с-17
BRPI0911422B8 (pt) 2008-04-18 2021-05-25 Reata Pharmaceuticals Inc compostos moduladores inflamatórios antioxidantes, composição farmacêutica e usos dos mesmos
EP2279197B1 (en) 2008-04-18 2014-11-05 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
WO2009134726A1 (en) 2008-04-28 2009-11-05 Abbott Laboratories Substituted pyrimidine derivatives as histamine h4 receptor ligands
AU2009274037B2 (en) 2008-07-22 2015-07-09 Trustees Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
WO2010053817A1 (en) 2008-11-04 2010-05-14 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
MY173715A (en) 2009-02-13 2020-02-18 Reata Pharmaceuticals Inc Delayed release, oral dosage compositions that contain amorphous cddo-me
NZ602826A (en) 2010-04-12 2014-11-28 Reata Pharmaceuticals Inc Method of treating obesity using antioxidant inflammation modulators
TWI527788B (zh) 2010-12-17 2016-04-01 瑞塔醫藥有限責任公司 作為抗氧化發炎調節劑之吡唑及嘧啶三環烯酮
RS59200B1 (sr) 2011-03-11 2019-10-31 Reata Pharmaceuticals Inc Derivati c4-monometil triterpenoida i postupci za njihovu upotrebu
ES2634315T3 (es) 2012-04-27 2017-09-27 Reata Pharmaceuticals, Inc. Derivados de 2.2-difluoropropionamida de bardoxolona metilo, formas polimórficas y métodos de uso de los mismos
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9593074B2 (en) 2012-09-10 2017-03-14 Reata Pharmaceuticals, Inc. C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
PT2892911T (pt) 2012-09-10 2017-11-02 Reata Pharmaceuticals Inc Derivados c17-heteroarilo de ácido oleanólico e seus métodos de uso
TWI716341B (zh) 2013-08-23 2021-01-21 美商瑞塔醫藥有限責任公司 使用齊墩果酸（ｂａｒｄｏｘｏｌｏｎｅ ｍｅｔｈｙｌ）或其類似物治療和預防內皮功能障礙之方法
MX372772B (es) 2014-01-24 2020-06-29 Reata Pharmaceuticals Inc Enonas piridazolilo y pirimidinilo tricíclicas sustituidas con arilo y arilalquilo como moduladores de la inflamación antioxidantes.
CA2953306C (en) * 2014-06-25 2023-10-31 Piramal Enterprises Limited Fused triterpene compounds and uses thereof
WO2016084790A1 (ja) * 2014-11-25 2016-06-02 第一三共株式会社 ヒドロナフトキノリン誘導体
WO2016130927A1 (en) 2015-02-12 2016-08-18 Reata Pharmaceuticals, Inc. Imidazolyl tricyclic enones as antioxidant iflammation modulators
SI3433256T1 (sl) 2016-10-24 2019-11-29 Astrazeneca Ab Derivat 6,7,8,9-tetrahidro-3H-pirazolo(4,3-f)izokinolina uporabni v zdravljenju raka
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
CR20190289A (es) 2016-12-16 2019-08-21 Pfizer Agonistas receptores de glp-1 y usos de los mismos
EP3555050A1 (en) 2016-12-16 2019-10-23 Basf Se Pesticidal compounds
UA125042C2 (uk) 2016-12-16 2021-12-29 Янссен Фармацевтика Нв Малі молекули-інгібітори кіназ родини jak
TWI831738B (zh) * 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
CN112654610B (zh) 2018-06-15 2024-12-24 里亚塔医药公司 用于抑制IL-17和RORγ的吡唑和咪唑化合物
WO2019246461A1 (en) 2018-06-20 2019-12-26 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith

Also Published As

Publication number Publication date
PE20191490A1 (es) 2019-10-21
TWI831738B (zh) 2024-02-11
IL267274A (en) 2019-08-29
AU2017377852C1 (en) 2025-11-13
US20200131148A1 (en) 2020-04-30
NZ754764A (en) 2023-04-28
CA3223645A1 (en) 2018-06-21
JP7177059B2 (ja) 2022-11-22
CO2019007409A2 (es) 2019-07-31
EA201991387A1 (ru) 2019-12-30
AU2017377852A1 (en) 2019-07-11
CN110248932B (zh) 2023-03-10
US20220135534A1 (en) 2022-05-05
WO2018111315A1 (en) 2018-06-21
CN110248932A (zh) 2019-09-17
CA3046183A1 (en) 2018-06-21
EP3555062A1 (en) 2019-10-23
MX2019007088A (es) 2019-10-15
US11292781B2 (en) 2022-04-05
AU2017377852B2 (en) 2022-02-17
IL267274B2 (en) 2024-03-01
KR20240019389A (ko) 2024-02-14
UA127376C2 (uk) 2023-08-02
BR112019012271A2 (pt) 2019-12-03
IL267274B1 (en) 2023-11-01
TW201835051A (zh) 2018-10-01
WO2018111315A8 (en) 2019-07-11
PH12019501371A1 (en) 2019-10-28
US12195443B2 (en) 2025-01-14
ZA201904227B (en) 2024-02-28
CA3046183C (en) 2024-02-20
KR20190110089A (ko) 2019-09-27
JP2020512289A (ja) 2020-04-23
US20250188053A1 (en) 2025-06-12

Similar Documents

Publication Publication Date Title
CL2019001658A1 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos.
ECSP19070369A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2020000747A1 (es) Formulaciones de niraparib.
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19070413A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
SV2018005750A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
MX2021004566A (es) Compuestos terapeuticos.
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
BR112019005318A2 (pt) compostos de aza-indazol para uso em lesões no tendão e/ou ligamento
MX2020012058A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cancer.
MX2019012522A (es) Compuestos y metodos terapeuticos.
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
CL2021000930A1 (es) Piridazinas novedosas
BR112017003227A2 (pt) composto, composição farmacêutica e uso de um composto
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.
MX2019014436A (es) Derivados de piridoquinazolina eficaces como inhibidores de proteina quinasa.